- Home
- KIND vs PHVS Comparison
KIND vs PHVS Comparison
Compare KIND & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIND
- PHVS
- Stock Information
- Founded
- KIND 2011
- PHVS 2015
- Country
- KIND United States
- PHVS Netherlands
- Employees
- KIND N/A
- PHVS N/A
- Industry
- KIND Computer Software: Programming Data Processing
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- KIND Technology
- PHVS Health Care
- Exchange
- KIND Nasdaq
- PHVS Nasdaq
- Market Cap
- KIND 974.5M
- PHVS 1.0B
- IPO Year
- KIND N/A
- PHVS 2021
- Fundamental
- Price
- KIND $2.42
- PHVS $19.57
- Analyst Decision
- KIND Hold
- PHVS Strong Buy
- Analyst Count
- KIND 2
- PHVS 5
- Target Price
- KIND $2.75
- PHVS $40.60
- AVG Volume (30 Days)
- KIND 2.4M
- PHVS 110.9K
- Earning Date
- KIND 11-06-2024
- PHVS 11-13-2024
- Dividend Yield
- KIND N/A
- PHVS N/A
- EPS Growth
- KIND N/A
- PHVS N/A
- EPS
- KIND N/A
- PHVS N/A
- Revenue
- KIND $237,605,000.00
- PHVS N/A
- Revenue This Year
- KIND $14.90
- PHVS N/A
- Revenue Next Year
- KIND $14.61
- PHVS N/A
- P/E Ratio
- KIND N/A
- PHVS N/A
- Revenue Growth
- KIND 9.99
- PHVS N/A
- 52 Week Low
- KIND $1.32
- PHVS $15.37
- 52 Week High
- KIND $3.00
- PHVS $33.00
- Technical
- Relative Strength Index (RSI)
- KIND 41.53
- PHVS 47.85
- Support Level
- KIND $2.26
- PHVS $18.01
- Resistance Level
- KIND $2.68
- PHVS $20.17
- Average True Range (ATR)
- KIND 0.13
- PHVS 1.33
- MACD
- KIND -0.03
- PHVS 0.01
- Stochastic Oscillator
- KIND 16.04
- PHVS 56.45
About KIND Nextdoor Holdings Inc.
Nextdoor Holdings Inc is the platform to connect to the neighborhoods. The purpose is to cultivate a kinder world where everyone has a neighborhood. Neighbors around the world turn to Nextdoor daily to receive trusted information, give and get help, get things done, and build real-world connections with nearby neighbors, businesses, and public services.
About PHVS Pharvaris N.V.
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development and commercialization of therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases. The company's activities are considered to be one segment which comprises the discovery, development and commercialization of oral bradykinin-B2-receptor antagonists .